• MA SHABBIR Family Medicine, PHCC (PRIMARY Healthcare Corporation) Qatar Locum GP NHS, UK
  • U KHAN Family Medicine, Primary Health Care Cooperation Qatar and Locum NHS Consultant, UK
  • GR LATIF Medicine, Complex Teaching Hospital Abbottabad, Pakistan
  • S ZAHRA Akhtar Saeed Medical and Dental College, Lahore, Pakistan
  • UB BUTT Ghuki Trust Teaching Hospital, Lahore, Pakistan



Hemangioma, Infant, Propranolol, Therapeutics, Treatment Outcome


Infantile hemangiomas (IHs) are common vascular tumors affecting pediatric populations, often necessitating medical intervention due to their potential for complications. Propranolol has emerged as a promising therapeutic option for IHs, although optimal dosing regimens and treatment outcomes remain areas of ongoing research. This prospective observational study aimed to evaluate the therapeutic efficacy, safety profile, and clinical characteristics associated with propranolol treatment in pediatric patients with IHs. Eighty infants aged one month to 1 year were included in the study, with IH occurrence and treatment initiation predominantly observed within the first 12 months of life. Propranolol was administered orally at a starting dose of 2 mg/kg/day, titrated up to 3-4 mg/kg/day as tolerated. Assessment of therapeutic response revealed significant reductions in IH size and vascularity, with 31.3% of patients demonstrating an excellent response and 37.5% showing a good response. Adverse effects were minimal, with diarrhea (22.5%) and decreased heart rate (7.5%) being the most commonly reported side effects. Anatomical distribution analysis identified the parotid region as the most common site of lesion occurrence, highlighting the heterogeneous nature of IHs. Overall, our findings support the favorable outcomes of propranolol therapy in pediatric patients with IHs, emphasizing the need for individualized treatment approaches tailored to patient-specific characteristics.


Download data is not yet available.


Bhartiya, M., Bhartiya, P., Krishna, S., Jha, A., Chandru, A. L., Ghosh, A., and Sen, D. (2022). Platform Abstracts. Annals of Indian Academy of Neurology 25, 3.

Darrow, D. H., Greene, A. K., Mancini, A. J., Nopper, A. J., Section on Dermatology, S. o. O. H., Neck Surgery, Surgery, S. o. P., Antaya, R. J., Cohen, B., Drolet, B. A., Fay, A., and Fishman, S. J. (2015). Diagnosis and management of infantile hemangioma. Pediatrics 136, e1060-e1104.

Greene, A. K., and Goss, J. A. (2018). Vascular anomalies: from a clinicohistologic to a genetic framework. Plastic and reconstructive surgery 141, 709e-717e.

Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., Horii, K. A., Lucky, A. W., Mancini, A. J., Metry, D. W., and Newell, B. (2007). Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. The Journal of pediatrics 150, 291-294.

Hochman, M. (2022). Timing and Rationale of Treatment. Vascular Anomalies, An Issue of Dermatologic Clinics, E-Book: Vascular Anomalies, An Issue of Dermatologic Clinics, E-Book 40, 379-382.

Hogeling, M., Adams, S., and Wargon, O. (2011). A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 128, e259-e266.

Ji, Y., Chen, S., Yang, K., Zhang, X., Zhou, J., Li, L., Xiang, B., Qiu, T., Dai, S., and Jiang, X. (2021). Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngology–Head & Neck Surgery 147, 599-607.

Kim, J., Hong, J. W., Roh, T. S., and Lee, W. J. (2018). Oral propranolol therapy in 23 infants with infantile hemangioma. Archives of Plastic Surgery 45, 517-524.

Koh, S. P., Leadbitter, P., Smithers, F., and Tan, S. T. (2020). β-blocker therapy for infantile hemangioma. Expert Review of Clinical Pharmacology 13, 899-915.

Krowchuk, D. P., Frieden, I. J., Mancini, A. J., Darrow, D. H., Blei, F., Greene, A. K., Annam, A., Baker, C. N., Frommelt, P. C., and Hodak, A. (2019). Clinical practice guideline for the management of infantile hemangiomas. Pediatrics 143.

Kum, J. J., and Khan, Z. A. (2014). Mechanisms of propranolol action in infantile hemangioma. Dermato-endocrinology 6, e979699.

Kumanyika, S. K., Obarzanek, E., Stettler, N., Bell, R., Field, A. E., Fortmann, S. P., Franklin, B. A., Gillman, M. W., Lewis, C. E., and Poston, W. C. (2008). Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). Circulation 118, 428-464.

Léauté-Labrèze, C., De La Roque, E. D., Hubiche, T., Boralevi, F., Thambo, J.-B., and Taïeb, A. (2008). Propranolol for severe hemangiomas of infancy. New England Journal of Medicine 358, 2649-2651.

Léauté-Labrèze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R. J., Caceres, H., Lopez Gutierrez, J. C., and Ballona, R. (2015). A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine 372, 735-746.

Lou, Y., Peng, W. j., Cao, Y., Cao, D. s., Xie, J., and Li, H. h. (2014). The effectiveness of propranolol in treating infantile haemangiomas: a meta‐analysis including 35 studies. British journal of clinical pharmacology 78, 44-57.

Marqueling, A. L., Oza, V., Frieden, I. J., and Puttgen, K. B. (2013). Propranolol and infantile hemangiomas four years later: a systematic review. Pediatric dermatology 30, 182-191.

Mohanty, P. K., Patel, J., Mohanty, H. K., Jena, P. K., Tripathy, P., Mohaptra, R., Dash, M., and Sarangi, G. (2018). A randomised controlled study on efficacy of propranolol, prednisolone and propranolol with prednisolone in infantile hemangioma. Journal of the Pediatrics Association of India 7, 166.

Munden, A., Butschek, R., Tom, W., Marshall, J. S., Poeltler, D. M., Krohne, S., Alió, A., Ritter, M., Friedlander, D., and Catanzarite, V. (2014). Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. British Journal of Dermatology 170, 907-913.

Organization, W. H. (2021). "Global patient safety action plan 2021-2030: towards eliminating avoidable harm in health care," World Health Organization.

Sans, V., de la Roque, E. D., Berge, J. r. m., Grenier, N., Boralevi, F., Mazereeuw-Hautier, J., Lipsker, D., Dupuis, E., Ezzedine, K., and Vergnes, P. (2009). Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 124, e423-e431.

Schiestl, C., Neuhaus, K., Zoller, S., Subotic, U., Forster-Kuebler, I., Michels, R., Balmer, C., and Weibel, L. (2011). Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. European journal of pediatrics 170, 493-501.

Schupp, C. J., Kleber, J. B., Günther, P., and Holland‐Cunz, S. (2011). Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatric dermatology 28, 640-644.

Storch, C., and Hoeger, P. (2010). Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. British Journal of Dermatology 163, 269-274.

Zheng, J. W., Zhang, L., Zhou, Q., Mai, H. M., Wang, Y. A., Fan, X. D., Qin, Z. P., Wang, X. K., and Zhao, Y. F. (2013). A practical guide to treatment of infantile hemangiomas of the head and neck. International journal of clinical and experimental medicine 6, 851.




How to Cite